Align Technology
ALGN
$168.05
+0.62%
Align Technology is the leading manufacturer of clear aligners, primarily known for its Invisalign brand, and also produces iTero intraoral scanners for digital dentistry. The company dominates the clear aligner market with over 90% market share and has treated over 14 million patients since launch, positioning it as the undisputed leader in orthodontic technology. The current investor narrative centers on a potential turnaround driven by activist investor Elliott Management's reported stake, which has sparked optimism about operational improvements and value creation. Additionally, the stock is under scrutiny as it trades well below historical valuation multiples, with debates around growth deceleration and margin expansion prospects.…
ALGN
Align Technology
$168.05
Related headlines
ALGN 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Align Technology's 12-month outlook, with a consensus price target around $210.29 and implied upside of +25.1% versus the current price.
Average Target
$210.29
0 analysts
Implied Upside
+25.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$175 - $240
Analyst target range
Align Technology is covered by 14 analysts, with a consensus recommendation of 'Buy' (mean rating 1.875 on a 1-5 scale where 1 is Strong Buy). The average target price is $210.29, implying 25.9% upside from the current price of $167.02. The distribution shows a bullish leaning, with no sell ratings in the recent data. The target range spans from $175.00 (low) to $240.00 (high), representing a spread of $65.00 or 38.9% of the current price, indicating moderate uncertainty. The high target of $240.00 assumes a return to historical growth rates and multiple expansion, while the low target of $175.00 may reflect concerns about continued margin compression or competitive pressures. Recent ratings actions include upgrades from Barclays (to Overweight in March 2026) and HSBC (to Buy in February 2026), suggesting improving sentiment. The wide spread between low and high targets highlights the binary nature of the activist-driven turnaround story.
Bulls vs Bears: ALGN Investment Factors
Align Technology presents a classic turnaround debate: a dominant market leader with a pristine balance sheet and activist catalyst, but facing decelerating growth and a prolonged downtrend. The bull case rests on margin expansion, forward valuation discount, and Elliott Management's potential to drive operational improvements, while the bear case highlights slowing revenue, high PEG ratio, and persistent underperformance. The single most important tension is whether the company can re-accelerate growth or at least stabilize it above 6-7% while expanding margins, as the forward P/E of 13.5x already prices in a significant earnings recovery. If growth disappoints, the stock could re-test its 52-week low of $122; if the activist succeeds, the stock could approach the analyst high target of $240. Currently, the evidence slightly favors the bull case given the low forward multiple and activist catalyst, but the risk of continued deceleration is material.
Bullish
- Activist Catalyst from Elliott Management: Elliott Management's reported stake in Align Technology provides a powerful catalyst to unlock value, as evidenced by the stock jumping on the news. Activist involvement often drives operational improvements, cost cuts, or strategic alternatives, which could accelerate margin expansion and shareholder returns.
- Strong Balance Sheet and Cash Flow: Align has a debt-to-equity ratio of just 0.028, virtually no leverage, and $1.06 billion in cash. Free cash flow was $120 million in Q1 2026, and trailing twelve-month FCF is $686 million, providing ample liquidity for buybacks, investments, or M&A.
- Margin Expansion Trajectory: Gross margin improved from 65.7% in Q4 2025 to 70.8% in Q1 2026, and operating margin rose from 15.2% to 16.6% over the same period. This demonstrates successful cost management and operating leverage, which could drive earnings growth even with modest revenue increases.
- Attractive Forward Valuation: The forward P/E of 13.5x is significantly below the trailing P/E of 27.6x, implying the market expects a sharp earnings recovery. This low multiple, combined with a consensus analyst target of $210.29 (25.9% upside), suggests the stock is undervalued relative to its earnings potential.
Bearish
- Revenue Growth Deceleration: Revenue growth has slowed from 10.5% YoY in Q2 2024 to just 6.2% in Q1 2026. This deceleration raises concerns about market saturation and competitive pressures, especially as the clear aligner market matures and alternative products emerge.
- High PEG Ratio Indicates Overvaluation: The PEG ratio stands at 51.8x, which is extremely high and suggests that the current stock price is not justified by the expected earnings growth rate. This implies that even modest growth disappointments could lead to multiple compression.
- Significant Underperformance vs Market: Align has declined 17.4% over the past year compared to the S&P 500's gain of 16.5%, with a relative strength of -33.9%. The stock is in a sustained downtrend, trading at 56% of its 52-week range, indicating persistent selling pressure and weak investor sentiment.
- High Volatility and Short Interest: With a beta of 1.669, the stock is 67% more volatile than the market, amplifying downside risk. The short ratio of 4.39 days suggests elevated bearish sentiment, and a high short interest could lead to a short squeeze but also reflects skepticism about the turnaround.
ALGN Technical Analysis
Align Technology is in a sustained downtrend, with the stock declining 17.4% over the past year compared to the S&P 500's gain of 16.5%. The current price of $167.02 sits at 56% of its 52-week range ($122.00–$208.31), indicating it is closer to the low end, which could suggest a value opportunity but also reflects persistent selling pressure. The 1-year relative strength of -33.9% underscores significant underperformance versus the market. Over the past three months, the stock has fallen 11.9%, while the S&P 500 rose 3.5%, showing continued weakness. However, the 1-month change of -2.3% is less severe than the 3-month decline, hinting at a potential deceleration in selling momentum. The relative strength over 1 month is -3.1%, slightly negative but improving from the 3-month reading of -15.4%, which could signal early stabilization. The 52-week low of $122.00 provides a key support level, while the 52-week high of $208.31 acts as resistance. A breakout above $208.31 would signal a reversal of the downtrend, while a breakdown below $122.00 could accelerate losses. The beta of 1.669 indicates the stock is 67% more volatile than the market, meaning larger swings in both directions, which is critical for risk management.
Beta
1.67
1.67x market volatility
Max Drawdown
-39.7%
Largest decline past year
52-Week Range
$122-$208
Price range past year
Annual Return
-18.2%
Cumulative gain past year
| Period | ALGN Return | S&P 500 |
|---|---|---|
| 1m | -5.8% | +1.4% |
| 3m | -5.2% | +3.9% |
| 6m | +1.9% | +6.3% |
| 1y | -18.2% | +16.0% |
| ytd | +7.7% | +8.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALGN Fundamental Analysis
Revenue growth has been modest but positive, with Q1 2026 revenue of $1.04 billion, up 6.2% year-over-year. However, the growth rate has decelerated from 10.5% in Q2 2024 to 6.2% in Q1 2026, indicating a slowing trajectory. The Clear Aligner segment generated $794 million in Q1 2026, while Scanners and Services contributed $201 million, showing the core aligner business remains the primary driver. The company is profitable, with net income of $112.8 million in Q1 2026 and a net margin of 10.8%. Gross margin improved to 70.8% in Q1 2026 from 65.7% in Q4 2025, reflecting better cost management. Operating margin was 16.6% in Q1 2026, up from 15.2% in Q4 2025, indicating margin expansion. The balance sheet is strong, with a debt-to-equity ratio of just 0.028, virtually no leverage. Free cash flow was $120 million in Q1 2026, and the company has $1.06 billion in cash. Return on equity (ROE) is 10.1%, while return on assets (ROA) is 7.2%, both reasonable for a medical device company. The current ratio of 1.36 suggests adequate liquidity.
Quarterly Revenue
$1.0B
2026-03
Revenue YoY Growth
+6.2%
YoY Comparison
Gross Margin
70.8%
Latest Quarter
Free Cash Flow
$686093000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALGN Overvalued?
Since net income is positive, the trailing P/E ratio of 27.6x is the primary valuation metric. The forward P/E of 13.5x implies a significant earnings growth expectation, as the forward multiple is roughly half the trailing multiple, suggesting the market anticipates a sharp earnings increase. The P/E gap of 14.1x indicates optimism about future profitability. Compared to the industry, Align's trailing P/E of 27.6x is above the sector average (data not provided), but the forward P/E of 13.5x may be more attractive if growth materializes. Historically, the stock's trailing P/E has ranged from 20.7x (Q4 2025) to 97.6x (Q4 2022), so the current 27.6x is near the lower end of its historical band, suggesting it is trading at a discount to its own history. This could indicate a value opportunity if fundamentals improve, or reflect structural challenges if the lower multiple persists.
PE
27.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 21x~73x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Align's revenue growth deceleration from 10.5% to 6.2% YoY is a key risk, as it may indicate market saturation or competitive pressure. The company's net margin of 10.8% is respectable but could compress if growth slows further or if the company invests heavily in R&D or marketing to defend market share. With a debt-to-equity ratio of 0.028, financial leverage is minimal, but the high PEG ratio of 51.8x suggests that any earnings miss could trigger a sharp valuation reset. The reliance on the Invisalign brand for the majority of revenue (76% from clear aligners) creates concentration risk, and any disruption to the brand's reputation or regulatory changes could severely impact financials.
Market & Competitive Risks: Align trades at a trailing P/E of 27.6x, which is near the low end of its historical range (20.7x to 97.6x), but the forward P/E of 13.5x implies the market is pricing in a significant earnings recovery that may not materialize. The stock's beta of 1.669 makes it highly sensitive to macro factors such as interest rates and consumer spending, which could dampen demand for elective orthodontic procedures. Competitive threats from DTC aligner companies like SmileDirectClub (though bankrupt) and traditional braces remain, but Align's 90% market share provides a moat. Recent news of Elliott Management's stake could lead to activist-driven changes, which may be disruptive or fail to deliver value.
Worst-Case Scenario: If revenue growth continues to decelerate below 5% and margins fail to expand, the stock could re-test its 52-week low of $122.00, representing a 27% decline from the current price of $167.02. In a severe recession or if a major competitor emerges, the stock could fall further, potentially to $100 or below, based on historical drawdowns (max drawdown of -39.73% from recent highs). An investor could lose up to 35% or more in this adverse scenario, especially given the high beta and short interest.